Skip to main content
. 2023 Nov 20;14:1286618. doi: 10.3389/fimmu.2023.1286618

Table 2.

Comparison of measured serum factors that differed between participants with versus without S. aureus SSTI.

Classification1 Factor Median (IQR) 1 p-value2
Case
n=16
Control
n=51
Case vs Control
Pro-/anti-inflammatory IFNγ 3.0 (2, 7) 2.18 (1.5, 3.2) 0.068
GM-CSF 0.001 (0, 0.07) 0.07 (0, 0.12) 0.03*
IL10 0.35 (0.29, 0.68) 0.29 (0.21, 0.42) 0.03*
IL2 0.11 (0.07, 0.22) 0.15 (0.09, 0.18) 0.7
Chemokine Eotaxin 213 (19, 338) 269 (216, 372) 0.087
Eotaxin3 21 (17, 25) 20 (15, 29) 0.05*
IL16 244 (204, 271) 208 (167, 246) 0.074
IL8 0 (0,0) 2 (0, 67) 0.006*
MCP4 88 (72, 150) 115 (90, 115) 0.1
MIP1β 114 (77, 152) 136 (105, 158) 0.2
Th17 IL17A 2.64 (1.60, 3.04) 1.72 (1.20, 2.39) 0.018*
IL17AF 0 (0, 0.1) 0.001 (0, 0.3) 0.6
IL17B 0.31 (0.14, 0.44) 0.67 (0.31, 0.97) 0.016*
IL17C 0 (0, 0.1) 0.00 (0.00, 0.00) >0.9
Vascular Injury CRP 2,162,710
(862,164, 7,718,677)
520,619
(284,546, 1,538,951)
0.014*
ICAM1 68,440
(463,980, 698,292)
391,945
(323,475, 593,272)
0.004*
VCAM1 612,265
(540,375, 752,649)
425,374
(355,599, 578,439)
<0.001*
SAA 1,928,395
(1,323,845, 5,521,066)
1,279,690
(751,070, 2,022,183)
0.045*
Angiogenesis Flt1 118 (111, 145) 142 (128, 180) 0.022*
VEGF 343 (139, 377) 139 (82, 202) 0.013*
VEGF-C 529 (486, 578) 533 (496, 690) 0.4
Growth Factors TSLP 0 0 0.4
IL7 13.7 (9.9, 18.0) 15.1 (11.2, 18.6) 0.7

1Factors grouped based on their biological functions. 2Data expressed as pg/ml serum cytokine concentration; 3p-value from Wilcoxon signed rank test. Asterisk ( * ) indicates statistical significance.